Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acebutolol in angina pectoris: objective assessment using graded treadmill testing.

A Kimchi, M S Gotsman, B S Lewis

    Israel Journal of Medical Sciences
    |September 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Changes in cIAP2, survivin and BimEL expression characterize the switch from autophagy to apoptosis in prolonged starvation.

    Journal of internal medicine·2017
    Same author

    Gender differences in the effects of cardiovascular drugs.

    European heart journal. Cardiovascular pharmacotherapy·2017
    Same author

    Cardiovascular pharmacotherapy.

    International journal of cardiology·2016
    Same author

    Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells.

    Gene therapy·2015
    Same author

    Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

    Circulation·2015
    Same author

    DAPK2 is a novel regulator of mTORC1 activity and autophagy.

    Cell death and differentiation·2014

    Acebutolol hydrochloride effectively treats angina pectoris by increasing exercise capacity and delaying symptom onset. This cardioselective beta-blocker demonstrates significant clinical benefits in patients with ischemic heart conditions.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Angina pectoris is a common condition characterized by chest pain due to myocardial ischemia.
    • Beta-adrenergic blocking drugs are frequently used to manage angina.
    • A new cardioselective beta-blocker, acebutolol hydrochloride, was investigated for its efficacy.

    Purpose of the Study:

    • To evaluate the clinical effects of acebutolol hydrochloride in patients with angina pectoris.
    • To assess the drug's impact on exercise tolerance and ischemic responses.

    Main Methods:

    • A randomized, placebo-controlled study involving 18 patients with angina pectoris.
    • Graded treadmill testing using a modified Bruce protocol.
    • Measurements included exercise capacity, electrocardiographic (ECG) changes, chest pain, heart rate, and blood pressure.

    Related Experiment Videos

    Main Results:

    • Acebutolol hydrochloride significantly increased the work performed before ischemic ECG changes and chest pain.
    • The drug blunted heart rate and blood pressure responses during exercise.
    • A greater workload was achieved at a lower double product (rate-pressure product) with acebutolol.

    Conclusions:

    • Acebutolol hydrochloride is effective in improving exercise tolerance in patients with angina pectoris.
    • Graded treadmill testing is a valuable tool for assessing the efficacy of beta-blocking agents.
    • The cardioselective nature of acebutolol may contribute to its favorable clinical profile.